Amorfix Life Sciences Ltd. ' Product Pipeline Review ' 2012
Summary
Global Market Direct's pharmaceuticals report, "Amorfix Life Sciences Ltd. - Product Pipeline Review - 2012" provides data on the Amorfix Life Sciences Ltd.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. This report is built using data and information sourced from Global Markets Direct's proprietary databases, Amorfix Life Sciences Ltd.'s corporate website, SEC filings, investor presentations and featured press releases, both from Amorfix Life Sciences Ltd. and industry-specific third party sources, put together by Global Markets Direct's team.
Scope
- Amorfix Life Sciences Ltd. - Brief Amorfix Life Sciences Ltd. overview including business description, key information and facts, and its locations and subsidiaries.- Review of current pipeline of Amorfix Life Sciences Ltd. human therapeutic division.- Overview of pipeline therapeutics across various therapy areas.- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.- Product profiles for late stage and clinical stage products of Amorfix Life Sciences Ltd. with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones. - Recent updates of the Amorfix Life Sciences Ltd.'s pipeline in the last quarter. - Key discontinued and dormant projects. - Latest news and deals relating to the products.
Reasons to buy
- Evaluate Amorfix Life Sciences Ltd.'s strategic position with total access to detailed information on its product pipeline. - Assess the growth potential of Amorfix Life Sciences Ltd. in its therapy areas of focus. - Identify new drug targets and therapeutic classes in the Amorfix Life Sciences Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas. - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps. - Exploit collaboration and partnership opportunities with Amorfix Life Sciences Ltd.. - Avoid Intellectual Property Rights related issues. - Explore the dormant and discontinued projects of Amorfix Life Sciences Ltd. and identify potential opportunities in those areas.
Abdominal Aortic Aneurysms Global Clinical Trials Review, H1, 2013
Amorfix Life Sciences Ltd. ' Product Pipeline Review ' 2012
1. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Amorfix Life Sciences Ltd. ' Product Pipeline Review ' 2012
Published on December 2012
Report Summary
Amorfix Life Sciences Ltd. ' Product Pipeline Review ' 2012
Summary
Global Market Direct's pharmaceuticals report, "Amorfix Life Sciences Ltd. - Product Pipeline Review - 2012" provides data on the
Amorfix Life Sciences Ltd.'s research and development focus. The report includes information on current developmental pipeline,
complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct's proprietary databases, Amorfix Life Sciences
Ltd.'s corporate website, SEC filings, investor presentations and featured press releases, both from Amorfix Life Sciences Ltd. and
industry-specific third party sources, put together by Global Markets Direct's team.
Scope
- Amorfix Life Sciences Ltd. - Brief Amorfix Life Sciences Ltd. overview including business description, key information and facts, and
its locations and subsidiaries.
- Review of current pipeline of Amorfix Life Sciences Ltd. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities,
across the globe.
- Product profiles for late stage and clinical stage products of Amorfix Life Sciences Ltd. with complete description of the product's
developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Amorfix Life Sciences Ltd.'s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate Amorfix Life Sciences Ltd.'s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Amorfix Life Sciences Ltd. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Amorfix Life Sciences Ltd.'s R&D portfolio and develop key strategic
initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Amorfix Life Sciences Ltd..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Amorfix Life Sciences Ltd. and identify potential opportunities in those areas.
Amorfix Life Sciences Ltd. ' Product Pipeline Review ' 2012 (From Slideshare) Page 1/6
2. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Table of Content
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Amorfix Life Sciences Ltd. Snapshot 6
Amorfix Life Sciences Ltd. Overview 6
Key Information 6
Key Facts 6
Amorfix Life Sciences Ltd. ' Research and Development Overview 7
Key Therapeutic Areas 7
Amorfix Life Sciences Ltd. ' Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products ' Monotherapy 10
Amorfix Life Sciences Ltd. ' Pipeline Products Glance 11
Amorfix Life Sciences Ltd. ' Early Stage Pipeline Products 11
Pre-Clinical Products/Combination Treatment Modalities 11
Discovery Products/Combination Treatment Modalities 12
Amorfix Life Sciences Ltd. ' Drug Profiles 13
ALS Therapeutic Vaccine 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
Anti-CD38 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
Anti-Fas 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
Anti-PrP Antibody 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
Antibodies Against Cancer 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
Amorfix Life Sciences Ltd. ' Pipeline Analysis 19
Amorfix Life Sciences Ltd. ' Pipeline Products by Therapeutic Class 19
Amorfix Life Sciences Ltd. ' Pipeline Products By Mechanism of Action 20
Amorfix Life Sciences Ltd. ' Recent Pipeline Updates 21
Amorfix Life Sciences Ltd. ' Company Statement 22
Amorfix Life Sciences Ltd. ' Product Pipeline Review ' 2012 (From Slideshare) Page 2/6
3. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Amorfix Life Sciences Ltd. ' Locations And Subsidiaries 24
Head Office 24
Financial Deals Landscape 25
Amorfix Life Sciences Ltd., Deals Summary 25
Amorfix Life Sciences Ltd., Pharmaceuticals & Healthcare, Deal Details 27
Asset Transactions 27
Amorfix Life Sciences Acquires Superoxide Dismutase-1 Technology From Dr. Neil Cashman 27
Partnerships 28
Amorfix Life Sciences Enters Into Licensing Agreement With JSW-Lifesciences 28
Amorfix Life Sciences Enters Into Agreement With Cangene To Develop Therapeutic Antibodies For Oncology 30
Amorfix Life Sciences Enters Into Co-Development Agreement With Helix BioPharma 31
Amorfix Life Sciences Enters Into Co-Development Agreement With QED Bioscience 32
Amorfix Life Sciences Enters Into An Agreement With Aragen Bioscience 33
Amorfix Enters Into Co-Development Agreement With Epitomics 34
Amorfix Life Sciences Enters Into An Agreement With BioMosaics 35
Amorfix Enters Into Co-Development Agreement With The University Of British Columbia 36
Amorfix Enters Into Co-Development Agreement With University Of British Columbia 37
Amorfix Signs An Agreement With Ontario Genomics 38
Licensing Agreements 39
Pan-Provincial Vaccine Enters Into Licensing Agreement With Amorfix Life Sciences 39
Amorfix Life Sciences Enters Into Licensing Agreement With Biogen Idec 40
Amorfix Life Sciences Enters Into Licensing Agreement With PREVENT 41
Amorfix Life Sciences Enters Into Licensing Agreement With University of British Columbia 42
Amorfix Life Sciences And Biogen Idec Enter Into Licensing Agreement 43
Amorfix Life Sciences Enters Into Licensing Agreement With University Health Network 44
Amorfix Life Sciences Enters Into Licensing Agreement With Dr. Neil Cashman 45
Equity Offering 46
Amorfix Life Sciences Completes Private Placement Of Units For $1 Million 46
Amorfix Life Sciences Completes Second Tranche Of Private Placement Of Units For $0.08 Million 47
Amorfix Life Sciences Completes Private Placement Of $0.51 Million 49
Amorfix Life Sciences Completes Private Placement Of $2.71 Million 51
Amorfix Completes Bought Deal Private Placement Of $8.63 Million 53
Amorfix Life Sciences Completes Private Placement Of $0.05 Million 55
Amorfix Completes Private Placement Of $3.04 Million 56
Amorfix Life Sciences Completes Private Placement Of $0.05 Million 58
Appendix 59
Methodology 59
Coverage 59
Secondary Research 59
Primary Research 59
Expert Panel Validation 59
Contact Us 60
Disclaimer 60
List of Tables
Amorfix Life Sciences Ltd. ' Product Pipeline Review ' 2012 (From Slideshare) Page 3/6
4. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Amorfix Life Sciences Ltd., Key Information 6
Amorfix Life Sciences Ltd., Key Facts 6
Amorfix Life Sciences Ltd. ' Pipeline by Indication, 2012 8
Amorfix Life Sciences Ltd. ' Pipeline by Stage of Development, 2012 9
Amorfix Life Sciences Ltd. ' Monotherapy Products in Pipeline, 2012 10
Amorfix Life Sciences Ltd. ' Pre-Clinical, 2012 11
Amorfix Life Sciences Ltd. ' Discovery, 2012 12
Amorfix Life Sciences Ltd. ' Pipeline By Therapeutic Class, 2012 19
Amorfix Life Sciences Ltd. ' Pipeline Products By Mechanism of Action, 2012 20
Amorfix Life Sciences Ltd. ' Recent Pipeline Updates, 2012 21
Amorfix Life Sciences Ltd., Deals Summary 25
Amorfix Life Sciences Acquires Superoxide Dismutase-1 Technology From Dr. Neil Cashman 27
Amorfix Life Sciences Enters Into Licensing Agreement With JSW-Lifesciences 28
Amorfix Life Sciences Enters Into Agreement With Cangene To Develop Therapeutic Antibodies For Oncology 30
Amorfix Life Sciences Enters Into Co-Development Agreement With Helix BioPharma 31
Amorfix Life Sciences Enters Into Co-Development Agreement With QED Bioscience 32
Amorfix Life Sciences Enters Into An Agreement With Aragen Bioscience 33
Amorfix Enters Into Co-Development Agreement With Epitomics 34
Amorfix Life Sciences Enters Into An Agreement With BioMosaics 35
Amorfix Enters Into Co-Development Agreement With The University Of British Columbia 36
Amorfix Enters Into Co-Development Agreement With University Of British Columbia 37
Amorfix Signs An Agreement With Ontario Genomics 38
Pan-Provincial Vaccine Enters Into Licensing Agreement With Amorfix Life Sciences 39
Amorfix Life Sciences Enters Into Licensing Agreement With Biogen Idec 40
Amorfix Life Sciences Enters Into Licensing Agreement With PREVENT 41
Amorfix Life Sciences Enters Into Licensing Agreement With University of British Columbia 42
Amorfix Life Sciences And Biogen Idec Enter Into Licensing Agreement 43
Amorfix Life Sciences Enters Into Licensing Agreement With University Health Network 44
Amorfix Life Sciences Enters Into Licensing Agreement With Dr. Neil Cashman 45
Amorfix Life Sciences Completes Private Placement Of Units For $1 Million 46
Amorfix Life Sciences Completes Second Tranche Of Private Placement Of Units For $0.08 Million 47
Amorfix Life Sciences Completes Private Placement Of $0.51 Million 49
Amorfix Life Sciences Completes Private Placement Of $2.71 Million 51
Amorfix Completes Bought Deal Private Placement Of $8.63 Million 53
Amorfix Life Sciences Completes Private Placement Of $0.05 Million 55
Amorfix Completes Private Placement Of $3.04 Million 56
Amorfix Life Sciences Completes Private Placement Of $0.05 Million 58
List of Figures
Amorfix Life Sciences Ltd. ' Pipeline by Indication, 2012 8
Amorfix Life Sciences Ltd. ' Pipeline by Stage of Development, 2012 9
Amorfix Life Sciences Ltd. ' Monotherapy Products in Pipeline, 2012 10
Amorfix Life Sciences Ltd. ' Pipeline By Therapeutic Class, 2012 19
Amorfix Life Sciences Ltd. - Pipeline Products By Mechanism of Action, 2012 20
Amorfix Life Sciences Ltd. ' Product Pipeline Review ' 2012 (From Slideshare) Page 4/6
5. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact
Order Information
Please verify that the product information is correct and select the format(s) you require.
Amorfix Life Sciences Ltd. ' Product Pipeline Review ' 2012
Product Formats
Please select the product formats and the quantity you require.
1 User License--USD 1 500.00 Quantity: _____
Site License--USD 3 000.00 Quantity: _____
Corporate License--USD 4 500.00 Quantity: _____
Contact Information
Please enter all the information below in BLOCK CAPITALS
Title: Mr Mrs Dr Miss Ms Prof
First Name: _____________________________ Last Name: __________________________________
Email Address: __________________________________________________________________________
Job Title: __________________________________________________________________________
Organization: __________________________________________________________________________
Address: __________________________________________________________________________
City: __________________________________________________________________________
Postal / Zip Code: __________________________________________________________________________
Country: __________________________________________________________________________
Phone Number: __________________________________________________________________________
Fax Number: __________________________________________________________________________
Amorfix Life Sciences Ltd. ' Product Pipeline Review ' 2012 (From Slideshare) Page 5/6
6. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.
Payment by credit card Card Number: ______________________________________________
Expiry Date __________ / _________
CVV Number _____________________
Card Type (ex: Visa, Amex…) _________________________________
Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189
Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE
Customer signature:
Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms
Please fax this form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
Amorfix Life Sciences Ltd. ' Product Pipeline Review ' 2012 (From Slideshare) Page 6/6